MedTrace Logo

Telmisartan in Prostate Cancer

NCT06168487 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-08-21

No results posted yet for this study

Summary

The goal of this clinical trial is to learn about the tolerability of telmisartan in patients with prostate cancer, but evidence for treatment efficacy will also be gathered.

Conditions

Interventions

DRUG

Telmisartan

Patients will be given telmisartan alone or with standard of care chemotherapy.

OTHER

Standard of Care Regimen

Standard of Care Regimen

Sponsors & Collaborators

  • Tyler J Curiel

    lead OTHER

Principal Investigators

  • Rodwell Mabaera, MD · Dartmouth Health

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-22
Primary Completion
2026-04-01
Completion
2027-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06168487 on ClinicalTrials.gov